Sera Prognostics, Inc. · NASDAQ:SERA
Sera Prognostics — Investor Presentation (January 2026)
38 slides from Sera Prognostics's investor presentation, Jan 8, 2026
Slide 1: Redefining pregnancy care to reduce the burden of preterm birth
JANUARY 2026 We are redefining pregnancy care to reduce the burden of preterm birth
Slide 2: Safe Harbor Statement
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue
Slide 3: Our Bold Ambition
Our vision is to become a global leader in high-value women’s health diagnostics. We’ll do this by taking a holistic approach to providing pivotal information to providers and patients—simultaneously enabling better health for moms and babies while improving the economics of healthcare delivery. Our
Slide 4: Corporate Overview: the need, the solution, commercial inflection
Reference: 1. Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: Final Data for 2022. Natl Vital Stat Rep. 2024 Apr;73(2):1-56. PMID: 38625869 2 Martin JA, Osterman MJK. Increases in neonatal intensive care admissions in the United States, 2016–2023. NCHS Data Brief. 2025 Mar;
Slide 5: The Need
THE Need
Slide 6: The US Has a Premature Birth Problem
THE US HAS A PREMATURE BIRTH PROBLEM And identification isn’t getting better National Vital Statistics Data: Infants were more likely to be admitted to a NICU in 2023 than in 2016, according to the Centers for Disease Control. The percentage of infants admitted rose from 8.7% to 9.8% FROM 2013-20243
Slide 7: Premature Birth Leads to 18X+ Higher Birth Cost of Newborns
HEALTH CARE COSTS OVER 7 YEARS Health Cost & Implications PREMATURE BIRTH LEADS TO 18X+ HIGHER BIRTH COST OF NEWBORNS Extremely Premature < 28 weeks Risk of death, long NICU stay, respiratory issues, decreased organ development, infections Premature < 32 weeks Respiratory issues, significant NICU s
Slide 8: How Effective Are Traditional Preterm Birth Screening Methods?
Reference: 1. Everyday Health Group Pregnancy & Parenting Insights, Bump Day Survey 2022; Q: “At your first prenatal appointment, what written materials did your doctor provide you with?” Saade GR, et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. A
Slide 9: Product and Science
PRODUCT AND Science
Slide 10: What Is a Proteomic Test?
THE PURPOSE Predictive test to detect biomarkers in the blood before symptoms arise WHAT IT MEASURES Risk of developing a condition, and biological effect HOW IT WORKS Uses advanced technologies (mass spectrometry) to analyze proteins and reveals patterns of protein expression and modification THE S
Slide 11: Blood-Based Biomarkers
BLOOD-BASED BIOMARKERS Specific proteins are associated with preterm birth risk IGFBP4 Insulin-like Growth Factor Binding Protein-4 Nutrient Delivery Reference: Saade GR, Boggess et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol
Slide 12: PreTRM Seamlessly Integrates Into Prenatal Care Workflows
Results delivered in an average of five days from a CLIA-certified, CAP-accredited lab Blood sample kits are provided for testing during 180/7-206/7 weeks with prepaid shipment to Sera’s lab Sample collection can be performed by staff and aligns with preexisting appointments ©2025 Sera Prognostics,
Slide 13: PreTRM Test Report
Pregnancies identified as higher risk by the PreTRM Test are at increased risk for*: Communicates a patient’s risk of spontaneous preterm birth & helps physicians engage with patients TEST REPORT Spontaneous preterm birth Severe adverse neonatal outcomes Longer neonatal hospital length of stay Refer
Slide 14: Robust Clinical Evidence
ROBUST CLINICAL Evidence —
Slide 15: Technology Platform and Exclusive Data Assets
Sera Drives Strategic Advantage to Deliver Clear Insights Rich Portfolio of Evidence 11+ Published Studies Biobank of Blood Samples 20,000 pregnant women EXCLUSIVE DATA ASSETS Advanced Mass Spectrometry 300+ proteins analyzed Artificial Intelligence & Machine Learning Discovering important predictor
Slide 16: The PreTRM Test: Only Clinically Validated Early Predictor
The PreTRM® Test is highly predictive of spontaneous preterm birth with a single blood draw during 180/7 through 206/7 weeks of gestation2 Three Independent Studies (discovery, verification, validation) reported in a large, multi-center trial Published as Editor’s Choice article in American Journal
Slide 17: PRIME & AVERT Studies
PRIME & AVERT STUDIES Multiple studies demonstrate an effective approach to managing patients identified as higher risk with the PreTRM® Test PRIME STUDY The Randomized Controlled Trial Involved: 19 U.S. sites, including community practices and university-based or -associated medical centers Enrolle
Slide 18: PRIME Study Finds PreTRM Reduces Earliest Preterm Births
Finds PreTRM® Test Reduces Earliest Preterm Births & Newborn Complications A pioneering clinical trial assessing the efficacy of the PreTRM Test and preventive interventions in lowering the occurrence of adverse pregnancy outcomes. THE PRIME STUDY HIGHER RISK NOT HIGHER RISK NOT HIGHER RISK PRESENT-
Slide 19: Study Design of PRIME
Control Arm N=2492 Intent-To-Treat N=2390 Screened Arm N=2526 Enrolled & Randomized 1:1 N=5018 Intent-To-Treat N=1851 Intent-To-Treat (ITT): The intent-to-treat (ITT) population comprised all randomized participants with outcome data and was used for the primary analysis of all trial outcomes. STUDY
Slide 20: PRIME: A Prospective, Randomized Controlled Trial
Recruitment November 2020-December 2023 The study was presented as an oral abstract at the 2025 SMFM Annual Pregnancy Meeting Included a diverse population with no significant differences in patient demographics in the control vs treatment arm. Demonstrates Significant Improvements in Neonatal Outco
Slide 21: Each Day Matters
EACH DAY MATTERS Maternal Focused Strategies Help Increase Gestational Age Reducing Deliveries Before 32 Weeks 56% reduction in deliveries before 32 weeks gestation1 Reducing Deliveries Before 35 Weeks 32% reduction in deliveries before 35 weeks gestation1 Increase in Gestational Age Gestational age
Slide 22: PRIME Demonstrates High Clinical Utility
PRIME DEMONSTRATES HIGH CLINICAL UTILITY Significantly improve neonatal outcomes Fewer health complications for newborns 20% reduction in odds of neonatal morbidity1 Decrease in NICU Admissions NICU admission decreased by 20%1 Cost Savings From PreTRM Screening A NICU day was saved for every 4.2 pat
Slide 23: PRIME Study Figure 2: Consistent Benefit
PRIME STUDY FIGURE 2. Consistent Benefit for Multiple Important Outcomes Reference: Iriye BK, O'Brien JM, Ennen CS, et al. Neonatal impact of maternal biomarker screening for risk of preterm birth with targeted interventions (PRIME): A multicenter, randomized, controlled trial. Pregnancy 2026;2(1):e
Slide 24: Proactive Care Strategies for Higher Risk Moms
PROACTIVE CARE STRATEGIES USED FOR HIGHER RISK MOMS Clear direction on managing higher-risk pregnancies Low-Dose Aspirin (81 mg) Taken orally daily until 366/7 weeks gestation Vaginal Progesterone (200 mg) Administered daily as a 200 mg micronized progesterone suppository until 366/7 weeks’ gestatio
Slide 25: Pathway to Commercialization
PATHWAY TO Commercialization PRESENT-105 rev 6.3
Slide 26: With PRIME Publication We Are Entering Commercialization Stage
WITH PRIME PUBLICATION We Are Entering Commercialization Stage Follows Key Milestones (Guidelines, Reimbursement) Market Adoption % Research & Development SERA FOUNDED 2026 PRIME STUDY PUBLISHED Broad Market Adoption Clinical Validation & Evidence Generation Targeted Adoption INFLECTION POINT ILLUS
Slide 27: Working to Activate the Ecosystem Within Each Geography
Working to Activate the Ecosystem Within Each Geography MULTI-STAKEHOLDER ACTIVATION MODEL State Medicaid Agency Hospital System/Provider Payer Alternative Partner Engaged with all tier 1 & 2 states 1 2 Ongoing conversations with payers in all targeted states As we build toward formal guidelines, ou
Slide 28: Targeted Geographies: 1st and 2nd Wave States
Shaping Next Wave with 4 States Accounting for an Additional 12% of US Births Medicaid-led innovation in maternal care (doulas, remote monitoring, home visits) Strong precedent for payers adopting new value-based solutions Geographic adjacency enables efficient sales and field coverage TARGETED GEOG
Slide 29: Commercialization Strategy in Two Parts
Targeted Adoption 2026 2027 2028 PRE-GUIDELINES Achieving coverage and reimbursement in target geographies building on provider momentum Partner pilots across first wave of target states, a key unlock SUCCESS FACTORS National Adoption POST-GUIDELINES National field sales presence Achieving broad cov
Slide 30: Real-World Pilots Play Key Role: Milestones and Timeline
12 6 0 18 24+ Selected Geographical Real-World Pilots Play Key Role Milestones & Timeline (in months) to Achieve Coverage EMR Integration with provider (if required) Review Pilot results with Plan and State Stakeholders Alignment on goals and pilot setup Time until 80-90% of claims for delivery subm
Slide 31: Reaching Payers with Health Economic Data
Illustrative impact for example small insurance plan 95% Confidence Interval Cumulative Net Impact Key assumptions: Covered lives: 812,000 Pregnancies/year: 8,607 Eligible for test: 88%; Screen Positive: 24% Intervention acceptance: 65% Cost: Test=$750 Cost of intervention=$1,200 Savings per person
Slide 32: Reaching Providers: Omni Channel Approach
LINKEDIN CAMPAIGNS PUBLIC RELATIONS EARNED MEDIA OMNI CHANNEL APPROACH Reaching Providers MEMBERS OF ACOG TARGETED VIA WEBINAR, NEWSLETTER & PRODUCT THEATRE DOXIMITY DEEP ENGAGEMENTS 5,000 DEEP ENGAGEMENT TARGETS VIA IMPIRICIOUS TEXT AWARENESS TO ADOPTION 2,300 45K ©2025 Sera Prognostics, Inc. All r
Slide 33: Reaching Moms with Premature Birth Education
Reaching Moms with Premature Birth Education WEEK 15 EMAIL PreTRM.com JAN 01 – AUG 04 REACH OF PREGNANT WOMEN 80% MILLION MONTHLY VISITORS 1.1 93% REACH OF FIRST TIME MOMS DIGITAL PARTNERSHIP 2025 SESSIONS: 161,309 2024 SESSIONS: 72,404 PRESENT-105 rev 6.3
Slide 34: 2026 Milestones: Driving Next Inflection Points
2026 Milestones Publications Guideline Conversations Commercialization Driving Next Inflection Points Payer Discussions Medicaid Pilot Expansions { ON THE HORIZON } PRESENT-105 rev 6.3
Slide 35: Ushers in a New Era of Personalized Pregnancy Care
Ushers in a new era of personalized pregnancy care THE PRETRM® TEST
Slide 36: Leadership Team
Leadership Team THE PRESENT-105 rev 6.3
Slide 37: Sera Leadership
Sera Leadership Zhenya Lindgardt President & CEO Former VP of Platform & Customer Engagement, Uber Technologies Former Senior Partner & Managing Director, The Boston Consulting Group Former CEO, The Commons Project Foundation MBA, Harvard University Former VP, Finance & Corporate Controller, Sera Fo
Slide 38: Together, We Can Do Better
Educate Providers. Empower Moms. HELP Babies. Advance Science. Elevate Care. Reach Maternity Deserts. Inform Payers. Evoke Change. TOGETHER, WE CAN DO BETTER PRESENT-105 rev 6.3
Sera Prognostics — Investor Presentation (January 2026) on 6ix